Blood Neuropeptide Y Levels Did Not Predict PTSD Development in Two Large Military Cohorts

Two longitudinal prospective cohort studies of military personnel were analyzed. Data collection began before deployment, with follow-up assessments completed up to two years after deployment. Plasma NPY levels were measured before and shortly after deployment using standard assays. PTSD symptoms were assessed at multiple time points using validated instruments. Three distinct NPY trajectories were identified using latent trajectory modeling. The relationship between NPY trajectories and PTSD symptom development was examined in both cohorts.

The military desperately needs biomarkers that can identify soldiers at risk for PTSD before they deploy, enabling targeted prevention. NPY was a promising candidate based on smaller studies showing that Special Forces soldiers (known for resilience) had higher NPY levels. This large, well-designed study's null finding is important — it redirects the search for PTSD biomarkers away from peripheral NPY and suggests that the relationship between NPY and stress resilience may be more complex than previously thought, potentially involving brain-specific rather than blood-based measurements.

This study illustrates an important principle in biomarker research: findings from small, specialized studies don't always replicate in larger populations. The NPY-resilience hypothesis was built on studies of elite military populations, but in broader military cohorts, the relationship doesn't hold for peripheral measurements. This doesn't mean NPY is irrelevant to stress — it likely means that blood NPY levels are too far removed from brain NPY activity to serve as a useful biomarker. The search for PTSD biomarkers continues, with growing interest in neuroimaging and genetic approaches.

Only peripheral (blood) NPY was measured, which may not reflect central nervous system NPY activity relevant to stress processing. The cohorts were predominantly male military personnel, limiting generalizability. PTSD symptoms were self-reported rather than clinician-diagnosed. The timing and frequency of NPY measurements may not capture dynamic stress-related NPY changes. Different assay methods between cohorts could introduce variability.